Source: Bloomberg
David Ricks, chairman and chief executive officer at Eli Lilly, discusses pricing pressures, the drug Trulicity, and the company’s commitment to Diabetes research. He speaks with Erik Schatzker on “Bloomberg Markets” from the JPMorgan Health Care conference in San Francisco.
